secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-044817
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q4 rev $22.5M (+11% YoY); closes Greenbrook TMS, guides FY25 rev $145-155M
--------------------------------------------------------------------------------

- Q4 2024 total revenue $22.5M (+11% YoY); U.S. treatment session revenue $12.9M; clinic revenue from Greenbrook $4.4M.
- Net loss Q4 $(12.2)M or $(0.33) per share vs $(5.4)M or $(0.19) in Q4 2023.
- Acquired Greenbrook TMS on Dec 9, 2024 adding 95 U.S. clinics; secured $10M from Perceptive Advisors at close.
- Realized over $21M of $22M targeted annualized cost synergies from Greenbrook integration.
- Completed $18.9M secondary offering in Feb 2025; guides FY25 rev $145-155M and Q3 2025 cash flow positive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312525044817/0001193125-25-044817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312525044817/d894924d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-044817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer